Kasanen, Henna http://orcid.org/0000-0003-0249-3374
Hernberg, Micaela http://orcid.org/0000-0002-0139-4596
Mäkelä, Siru http://orcid.org/0000-0002-5720-5993
Brück, Oscar
Juteau, Susanna
Kohtamäki, Laura http://orcid.org/0000-0002-9888-3635
Ilander, Mette http://orcid.org/0000-0001-9387-1179
Mustjoki, Satu http://orcid.org/0000-0002-0816-8241
Kreutzman, Anna http://orcid.org/0000-0002-5587-8844
Funding for this research was provided by:
K. Albin Johanssons Stiftelse
Medicinska Understödsföreningen Liv och Hälsa
Päivikki ja Sakari Sohlbergin Säätiö
Syöpäjärjestöt
Signe ja Ane Gyllenbergin Säätiö
Sigrid Juséliuksen Säätiö
Helsinki Institute of Life Sciences
Finnish Cancer Institute
State funding for university-level health research in Finland
Article History
Received: 20 August 2019
Accepted: 20 January 2020
First Online: 8 February 2020
Compliance with ethical standards
:
: Micaela Hernberg has received honoraria from Pierre Fabre, Novartis, Bristol-Myers Squibb (BMS), Merck Sharp & Dohme (MSD), Roche, Amgen, Sanofi and Incyte. Siru Mäkelä has had a paid consulting and advisory role with MSD, BMS, Novartis, Sanofi, Amgen and Roche. Satu Mustjoki has received honoraria and research funding from BMS and research funding from Novartis and Pfizer. The remaining authors declare no conflicts of interest.
: The study was approved by the Helsinki University Hospital ethical committee (healthy volunteers Dnro 303/12/03/01/2011 and melanoma patients Dnro 115/13/03/02/15). The study was conducted in accordance with the Declaration of Helsinki.
: All samples involving patients and healthy volunteers were taken after giving a signed informed consent. The patients and healthy volunteers consented to the use of their specimens in terms of data research and publication use.